Add Yahoo as a preferred source to see more of our stories on Google. Most people who've had a heart attack—or who fear having one—focus on surviving the cardiovascular event itself. But what happens ...

The FDA has granted Fast Track designation to invobenitug, an investigational anti-cDPP3 monoclonal antibody designed to restore RAAS balance in cardiogenic shock.

LONDON — Cardiogenic shock and recovering cardiac arrest have a checkered history when it comes to high-impact management strategies. Now, a new meta-analysis provides a clear steer on the value of ...

Numerous knowledge gaps exist regarding the care of female patients with cardiogenic shock, often because they have been consistently underrepresented in clinical trials, according to a new consensus ...

Physicians forced to make rapid-fire choices, with limited evidence, in acute myocardial infarction complicated by cardiogenic shock (AMICS) finally have what they’ve long been waiting for: positive ...

TEEN4 Pharmaceuticals GmbH today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to invobenitug (formerly known as procizumab), for the treatment of ...

More than a quarter of patients with early-stage cardiogenic shock had to be transferred to a higher level of care, progressed to a worse stage of shock, or died, according to a study in six US ...

ST. LOUIS – Cardiogenic shock is a serious and life-threatening condition that happens when the heart suddenly cannot pump enough blood to meet the body’s needs. It leads to dangerously low blood ...

Please provide your email address to receive an email when new articles are posted on . Cardiogenic shock is a strong independent predictor of in-hospital mortality in children with acute ...

Many survivors of cardiogenic shock showed evidence of new cognitive impairment after leaving the hospital, according to a study led by UT Southwestern Medical Center researchers. The findings, ...

Windtree Therapeutics, Inc. WINT, a biotechnology company treating late-stage acute cardiovascular disorders, is advancing its first-in-class drug for serious heart conditions. The company believes ...